Massachusetts Financial Services’s Alder Biopharmaceuticals ALDR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-611,039
| Closed | -$11.5M | – | 860 |
|
|
2019
Q3 | $11.5M | Sell |
611,039
-322,561
| -35% | -$3.69M | ﹤0.01% | 595 |
|
|
2019
Q2 | $11M | Buy |
933,600
+5,409
| +0.6% | +$65.5K | ﹤0.01% | 615 |
|
|
2019
Q1 | $12.7M | Buy |
928,191
+175,389
| +23% | +$2.27M | 0.01% | 587 |
|
|
2018
Q4 | $7.72M | Buy |
752,802
+15,514
| +2% | +$199K | ﹤0.01% | 631 |
|
|
2018
Q3 | $12.3M | Sell |
737,288
-110
| -0% | -$1.99K | 0.01% | 594 |
|
|
2018
Q2 | $11.7M | Buy |
737,398
+69,327
| +10% | +$1.05M | 0.01% | 610 |
|
|
2018
Q1 | $8.48M | Buy |
668,071
+364,580
| +120% | +$5.27M | ﹤0.01% | 637 |
|
|
2017
Q4 | $3.48M | Buy |
303,491
+3,973
| +1% | +$44.3K | ﹤0.01% | 681 |
|
|
2017
Q3 | $3.67M | Buy |
299,518
+151,809
| +103% | +$1.58M | ﹤0.01% | 673 |
|
|
2017
Q2 | $1.69M | Sell |
147,709
-31
| -0% | -$573 | ﹤0.01% | 723 |
|
|
2017
Q1 | $3.07M | Sell |
147,740
-233
| -0.2% | -$5.16K | ﹤0.01% | 684 |
|
|
2016
Q4 | $3.08M | Sell |
147,973
-377
| -0.3% | -$9.8K | ﹤0.01% | 698 |
|
|
2016
Q3 | $4.86M | Buy |
148,350
+2,509
| +2% | +$76.4K | ﹤0.01% | 652 |
|
|
2016
Q2 | $3.64M | Sell |
145,841
-45,641
| -24% | -$1.23M | ﹤0.01% | 677 |
|
|
2016
Q1 | $4.69M | Buy |
191,482
+5,684
| +3% | +$132K | ﹤0.01% | 647 |
|
|
2015
Q4 | $6.14M | Sell |
185,798
-134,885
| -42% | -$4.56M | ﹤0.01% | 629 |
|
|
2015
Q3 | $10.5M | Buy |
320,683
+70,683
| +28% | +$3.01M | 0.01% | 591 |
|
|
2015
Q2 | $13.2M | Buy |
+250,000
| New | +$9.09M | 0.01% | 581 |
|
Massachusetts Financial Services's ALDR Position: Q4 2019 in Review
Massachusetts Financial Services sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 611,039 shares — an estimated $11.5M sold.
Massachusetts Financial Services first reported a position in ALDR in Q2 2015 and held it in 18 quarters. The position peaked at $13.2M in Q2 2015. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.
- Massachusetts Financial Services reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
- Massachusetts Financial Services sold 611,039 Alder Biopharmaceuticals shares in Q4 2019, an estimated $11.5M.
- Massachusetts Financial Services first reported a position in Alder Biopharmaceuticals in Q2 2015 and held it in 18 quarters.
- Massachusetts Financial Services's Alder Biopharmaceuticals position peaked at $13.2M in Q2 2015.
- 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.
Based on Massachusetts Financial Services's 13F filing for Q4 2019, filed 13 Feb 2020.